Our Team Believes There’s a Better Way

By bringing together exceptional researchers, innovators, and entrepreneurs, STRM.BIO is opening the door to the future of medicine for patients worldwide with a better way to deliver gene therapies. Our team has founded biotech companies, developed effective therapies, and successfully brought new products to market. We have the drive, vision, and the experience to fulfill the promise of gene therapy

Michael Luther, Ph.D., MBA
Michael Luther, Ph.D., MBA
Chief Executive Officer
Michael Luther, Ph.D., MBA
Chief Executive Officer

Dr. Michael Luther has over 37 years’ experience as an entrepreneurial scientist and executive in the biopharmaceutical industry including various senior leadership roles ranging from biotech start-ups to global pharmaceutical companies and CROs. In addition to serving as STRM.BIO’s CEO, he is currently the managing partner for BioInnovations, LLC where he acts as a board member and consultant for various start up biotech companies. Previously, Mike led North American Business Development efforts for Astellas as Global Head of Search & Evaluation in Business Development and Astellas Ventures to support Astellas’ drug discovery and development efforts. This included over 9 deals signed and 2 NewCo spinouts in less than two years.

Before joining Astellas, Mike was the CEO and founder of Bantam Pharmaceutical, a biotech company focused on the clinical development of cancer therapeutics targeting the mitochondrial stress response pathway and targets. He remains an active advisor and member of the board of directors and their SAB. In other past roles, Mike was the Senior Vice President for Drug Discovery & Development at Curio and founding CEO for the David H. Murdock Research Institute at the North Carolina Research Campus, a public-private partnership created to accelerate bench to market activities in life sciences. Mike also has 20 years in various senior executive roles in the global pharmaceutical industry including Vice President and head of global drug discovery divisions for both Merck and GSK.

Mike holds Bachelor of Science degrees from North Carolina State University, a doctorate from St. Louis University School of Medicine, and an MBA from Duke University. He is the author of over 80 publications and patents.

Kevin White, Ph.D.
Kevin White, Ph.D.
Boehringer Ingelheim Venture Fund
Kevin White, Ph.D.
Kevin White, Ph.D.
Boehringer Ingelheim Venture Fund

Kevin is an Investment Manager focusing on strategic investments and new company creation, with emphasis on translating groundbreaking science into innovative medicines. He completed his postdoctoral studies in cellular biology at Harvard Medical School and his PhD at the University of Glasgow.

Tim Xiao
Tim Xiao
Delos Capital
Tim Xiao
Tim Xiao
Delos Capital

Tim Xiao, CFA, FRM, is a Partner and founding team member at Delos Capital since its inception in 2014. He has closed deals with an aggregate value of $4 billion, and serves as a director of Sichuan Clover Biopharmaceuticals, OncoMyx Therapeutics, Luqa Pharmaceuticals, Curatia Medical and Thermalin.​

Alex Eihgen, MD, PhD
Alex Eihgen, MD, PhD
Recordati Ventures
Alex Eihgen, MD, PhD
Alex Eihgen, MD, PhD
Recordati Ventures

Alex is a physician with a strong leadership and research background in the pharmaceutical industry. Over 15 years of industry experience with responsibilities in Pre-clinical Research, Biomarkers, Translational Medicine, and Clinical Drug Development.

Eric Huang, PhD
Eric Huang, PhD
Delos Capital
Eric Huang, PhD
Eric Huang, PhD
Delos Capital

Eric is a partner at Delos Capital. Previously, he was the General Manager and Chief Scientific Officer at Moderna Genomics. Eric was recognized with the prestigious Warren Alpert Foundation Prize for his pioneering work on the mRNA vaccine platform.

Connect with us
© STRM.BIO 2026